PathAI Announces Early Access Program to Drive Adoption of AISight Image Management System in Anatomic Pathology Laboratories Across Mainland Europe
21 Mayo 2024 - 2:00AM
Business Wire
AISight IMS enables pathology labs to be at the forefront of
emerging and state-of-the-art digital pathology technologies and
workflows.
PathAI, a global leader in AI-powered pathology, today announced
a new Early Access Program (EAP) to drive adoption of its AISightTM
Image Management System (IMS) in Mainland Europe.1 Earlier in 2023,
PathAI announced a similar program for laboratories in the United
States, which attracted over 50 laboratories with many exploring
long-term use of PathAI’s AISight Image Management System and broad
menu of AI Products.
As part of the EAP, AP Laboratories in Europe can trial AISight,
a modern and cloud-based digital pathology solution compliant with
GDPR, as well as conduct and publish real-world validation studies
of PathAI’s AI Products such as ArtifactDetect, TumorDetect,
AIM-TumorCellularity, AIM-PD-L1, and AIM-HER2.2
“We are thrilled to commence a more dedicated focus to bring
AISight Image Management System to labs in Europe. We have
continued to make improvements on the platform with input from our
first set of commercial customers in the U.S. We are excited to
partner with European labs in democratizing access to digital
pathology, enhancing pathologist experience, and ultimately
improving patient outcomes,” said Nick Brown, Chief Growth Officer
at PathAI.
AISight is a cloud-based platform that enables efficient
end-to-end digital pathology workflows. AISight provides
best-in-class caseload balancing and assignment, caselist
prioritization, image ingestion, image viewing, collaboration
tools, and image and case management. Via AISight Link, AISight can
also be integrated bidirectionally with laboratory information
systems for streamlined workflows. Anatomic pathology laboratories
of all sizes and specialties – including health systems, university
hospitals, and reference laboratories – may utilize AISight.
“PathAI has been an excellent thought partner for helping our
institution think through what it means to create a modern,
next-generation digital pathology workflow that spans versatile use
cases like research, clinical trials, and diagnostics,” said Prof.
Dr. Jan Budczies, Head of Medical Bioinformatics at the University
of Heidelberg. “We are excited to partner with PathAI on this Early
Access Program and look forward to taking advantage of their
growing portfolio of features and algorithms on AISight, starting
with our Molecular Pathology Department where we are especially
interested in understanding the feasibility of estimating tumor
cell content and characterizing immune cell infiltrates more
precisely by leveraging digital pathology and artificial
intelligence.”
AISight enables pathologists with seamless access to a broad
array of algorithms to drive workflow optimization, standardized
biomarker quantitation, and next-generation case prioritization
including ArtifactDetect, TumorDetect, AIM-TumorCellularity,
AIM-PD-L1 (NSCLC, HNSCC, Melanoma, Urothelial), and AIM-HER2 Breast
Cancer and will also host third-party algorithms on request.
“We have trialed AISight at our department for several months
now. At our Molecular Pathology Unit we are especially interested
in understanding the feasibility of estimating tumor cell content
through image analysis. PathAI’s AIM-TumorCellularity can be a tool
that will change time to treatment for patients in need of
molecular testing,” said Prof. Dr. Holger Moch, Director of
Pathology at the University of Zurich and PathAI Advisor. “PathAI
has been responsive to our unique needs and a valuable thought
partner in helping us think through how to pick the most modern and
innovative digital pathology solution on the market. We are excited
about our partnership with PathAI and look forward to taking
advantage of their growing portfolio of algorithms and feature
improvements on AISight.”
“We have been leveraging the AIM-PD-L1 NSCLC and
AIM-TumorCellularity NSCLC Algorithms over the past few months at
our institution as part of a large research cohort,” said Dr. Jose
Palacios, Director of Pathology at Ramon y Cajal Hospital in
Madrid, Spain. “Given the success we’ve seen at our own
institution, there has been increasing demand from across Spain to
leverage these algorithms and we are working with more than 10+
hospitals across Spain to implement these tools.”
PathAI expects IVDR Certification of AISight Dx for primary
diagnosis by Q3 2024. Early Access Program Participants will be the
first to receive access to this platform. To learn more about
AISight, visit our website. PathAI’s team will also be at upcoming
conferences including the European Congress of Digital Pathology in
Vilnius, Lithuania (June 5-8), European Congress of Pathology in
Florence, Italy (September 7-11), and the DP/AI Congress in London,
United Kingdom (December 7-8).
Footnotes
1 AISight™ is for research use only. Not for use in diagnostic
procedures.
2 ArtifactDetect™, TumorDetect™, AIM-TumorCellularity™,
AIM-PD-L1™ and AIM-HER2™ are research use only. Not for use in
diagnostic procedures.
About PathAI
PathAI is the only AI-focused technology company to provide
comprehensive precision pathology solutions from wet lab services
to algorithm deployment for clinical trials and laboratory use.
Rigorously trained and validated with data from more than 15
million annotations, its AI-powered models can be leveraged to
optimize the analysis of pathology samples to improve efficiency
and accuracy of pathology interpretation, as well as to better
gauge therapeutic efficacy and accelerate drug development for
complex diseases.
PathAI is headquartered in Boston, MA. For more information,
please visit www.pathai.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240521660078/en/
Maggie Naples SVM Public Relations and Marketing Communications
pathai@svmpr.com +1 401-490-9700